![banner](/mea/kw/sites/default/files/2023-09/media%402x.png)
Benefits Beyond Metabolic Control
In T2D, the heart and kidneys are still at risk, independent of metabolic control1
![Thumbnail Thumbnail](/mea/kw/sites/default/files/2023-09/01-elements-placeholder-card-1-1%403x.png)
CV disease
accounts for 50%
of deaths in patients with
T2D globally, and as
many as 50% of patients
may develop HF3,4
![Thumbnail Thumbnail](/mea/kw/sites/default/files/2023-09/01-elements-placeholder-card-1-1%403x_0.png)
Metabolic
94% of patients with
T2D have 21 cardio-renal
or metabolic condition?
![Thumbnail Thumbnail](/mea/kw/sites/default/files/2023-09/01-elements-placeholder-card-1-1%403x_1.png)
Diabetic Kidney
disease
occurs in 20%-40% of
patients with T2D and
contributes to CV and
all-cause mortality'
KDIGO guidelines 2022 update
24/04/2023 | Author: Boehringer Ingelheim
KDIGO guidelines 2022 update
Document ID: PC-KW-100645 | Expiry Date: 09/04/2025